DCGI okays emergency use of Zydus' two-jab Covid-19 vaccine for 12 yrs-plus

With this, vaccine will now be administered on day 0 and day 28. Earlier, it was approved as a triple dose on day 0, day 28 and day 56

Zydus vaccine

Photo: Bloomberg

Vinay Umarji Ahmedabad
The Drug Controller General of India (DCGI) has authorised emergency use (EUA) for Zydus Lifesciences Ltd's novel Covid-19 vaccine, ZyCoV-D as a two-dose vaccine, the company announced on Tuesday.

With this approval, the vaccine will now be administered on day 0 and day 28. Earlier, the vaccine was approved in a three dose regimen to be administered on day 0, day 28 and day 56.

The approval will increase the compliance for the vaccine and reduce the overall time required for vaccination to improve immunity against the virus, said Dr. Sharvil Patel, managing director of Zydus Lifesciences. "It will also help in administering the vaccine in a larger population in a shorter time which is always desirable in the midst of a

Also Read

Covid vaccine: Single-dose Sputnik Light gets DCGI nod for emergency use

Serum Institute applies for full marketing authorisation of Covishield

US allows automatic job authorisation for spouses of H1-B visa holders

Covid-19: Zydus gets SEC approval for two-dose regimen of ZyCov-D

Covid-19 pandemic: Covovax data with DCGI, approval expected soon

Adityanath stresses on conducting more tests to slow down Covid-19

Covid-19 cases in the country dip to 15,636; 2,483 fresh cases reported

Confusion, fear behind reluctance to take Covid booster, says experts

As Shanghai struggles with coronavirus, focus on Beijing as cases rise

DCGI grants EUA to Corbevax for those aged 5-12, Covaxin for 6-12 age group

First Published: Apr 26 2022 | 4:27 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com